切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2019, Vol. 13 ›› Issue (04) : 293 -299. doi: 10.3877/cma.j.issn.1674-1358.2019.04.006

所属专题: 文献

论著

闽南地区核苷(酸)类药物经治的乙型肝炎患者乙型肝炎病毒基因型与逆转录酶区耐药突变特点
张小曼1, 徐涛1,(), 许正锯1   
  1. 1. 362000 泉州市,中国人民解放军联勤保障部队第910医院肝病中心
  • 收稿日期:2019-01-30 出版日期:2019-08-15
  • 通信作者: 徐涛
  • 基金资助:
    泉州市科技计划项目(No. 2018N135S)

Characteristics of genotypes and resistant mutations within hepatitis B virus (HBV) reverse transcriptase sequences of nucleos(t)ide analogues experienced patients with HBV infection in southern Minnan region

Xiaoman Zhang1, Tao Xu1,(), Zhengju Xu1   

  1. 1. Liver Diseases Center, the 910th Joint Logistic Support Unit of the People’s Liberation Army of China, Quanzhou 362000, China
  • Received:2019-01-30 Published:2019-08-15
  • Corresponding author: Tao Xu
  • About author:
    Corresponding author: Xu Tao, Email:
引用本文:

张小曼, 徐涛, 许正锯. 闽南地区核苷(酸)类药物经治的乙型肝炎患者乙型肝炎病毒基因型与逆转录酶区耐药突变特点[J/OL]. 中华实验和临床感染病杂志(电子版), 2019, 13(04): 293-299.

Xiaoman Zhang, Tao Xu, Zhengju Xu. Characteristics of genotypes and resistant mutations within hepatitis B virus (HBV) reverse transcriptase sequences of nucleos(t)ide analogues experienced patients with HBV infection in southern Minnan region[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(04): 293-299.

目的

分析闽南地区核苷酸(类)药物(NAs)经治的乙型肝炎患者乙型肝炎病毒(HBV)基因型与逆转录酶区(RT)耐药突变特点。

方法

采用PCR产物直接测序法分析2012年1月至2017年12月中国人民解放军联勤保障部队第910医院肝病中心收治的524例HBV感染者HBV RT区K169~M250核苷酸序列。随访患者抗病毒治疗史,同时检测其血清中HBV e抗原(HBeAg)、HBV DNA、丙氨酸氨基转移酶(ALT)和天门冬氨酸氨基转移酶(AST)等水平。

结果

入组524例患者中,293例(55.92%)为HBV B型,231例(44.08%)为HBV C型。HBV B型和C型患者性别、HBeAg状态、病程、NAs药物选择、不同药物治疗方式下NAs相关耐药突变率、NAs用药时间及血清HBV DNA载量、ALT、AST水平差异均无统计学意义(P均> 0.05)。但HBV C型患者年龄(t = 6.486、P < 0.001)和NAs相关耐药突变率(64.94% vs. 51.88%,χ2 = 8.493、P = 0.003)显著高于HBV B型患者。524例患者中NAs相关耐药突变检出率为57.63%(302/524),204位点突变频率最高,其次为180、181和229。10个位点突变均伴随M204变异出现,包括169、173、180、200、202、207、214、237、245和250。HBV C型患者在9个位点上(180、181、184、191、200、221、224、229和238)的突变率显著高于B型患者,差异有统计学意义(P均< 0.05)。HBV B型患者在236和250位点的突变率显著高于C型患者(χ2 = 5.867、P = 0.015,χ2 = 4.226、P = 0.040)。M204相关的伴随突变在基因型B和C中亦表现出不同的倾向性:M204I突变更易出现在B型患者中,而L180 + M204I、T184 + L180 + M204V更易出现在C型患者中。

结论

在NAs药物选择压力下,HBV B型感染者和C型感染者表现出不同耐药突变特点。

Objective

To investigate the characteristics of hepatitis B virus (HBV) genotype and reverse transcriptase region (RT) resistance mutation of hepatitis B patients treated with nucleos(t)ide analogues (NAs) in southern Minnan region.

Methods

The K169-M250 nucleotides in HBV RT region of 524 patients with hepatitis B admitted to Liver Diseases Center, the 910th Joint Logistic Support Unit of the People’s Liberation Army of China from January 2012 to December 2017 were analyzed by direct sequencing of PCR products. The patients were followed up after antiviral therapy, and the levels of HBV e antigen (HBeAg), HBV DNA, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum were detected, respectively.

Results

Among the enrolled 524 patients, 293 cases (55.92%) were HBV genotype B and 231 cases (44.08%) were HBV genotype C. The sex, HBeAg status, course of disease, selection of NAs drug, mutation rate of drug resistance after NAs application, period of NAs application and serum HBV DNA level, levels of ALT and AST were not significantly different (all P > 0.05). However, the age of patients with HBV genotype C (t = 6.486, P < 0.001) and mutation rates of NAs related drug resistance (64.94% vs. 51.88%; χ2 = 8.493, P = 0.003) were significantly higher than those of patients with HBV genotype B, with significant differences. Among the 524 patients, the detection rate of NAs related drug resistance mutation was 57.63% (302/524), and the frequency of mutation at site 204 was the highest, followed by 180, 181 and 229 sites. Ten mutations with M204 mutation were found, including 169, 173, 180, 200, 202, 207, 214, 237, 245 and 250 sites. The mutation rates of patients with HBV genotype C at 9 sites (180, 181, 184, 191, 200, 221, 224, 229 and 238 sites) were significantly higher than those of patients with HBV genotype B, with significant differences (all P < 0.05). The mutation rates of HBV B-type patients at 236 and 250 sites were significantly higher than those of C-type patients (χ2 = 5.867, P = 0.015; χ2 = 4.226, P = 0.040). The mutation associated with M204 also showed different tendency in HBV genotype B and C: M204I mutation was more likely to occur in patients with genotype B, and L180 + M204I, T184 + L180 + M204V were more likely to be present in patients with genotype C.

Conclusion

Under the pressure of NAs drug selection, HBV genotype B and C infection showed different characteristics of drug resistances mutation.

表1 HBV RT区潜在耐药突变位点[3]
表2 HBV B型和C型感染者的临床特征
临床特征 例数 HBV B型(293例) HBV C型(231例) 统计量 P
性别[例(%)] ? ? ? χ2 = 0.493 0.483
? 430 244(56.74) 186(43.26) ? ?
? 94 49(52.13) 45(47.87) ? ?
HBeAg [例(%)] ? ? ? χ2 = 0.010 0.919
? (+) 406 227(55.96) 179(44.04) ? ?
? (-) 118 66(53.85) 52(46.15) ? ?
病程[例(%)] ? ? ? χ2 = 4.821 0.090
? CHB 428 250(57.94) 178(42.06) ? ?
? LC 68 27(39.71) 41(60.29) ? ?
? PHC 28 11(39.29) 17(60.71) ? ?
NAs药物选择[例(%)] ? ? ? χ2 = 6.030 0.197
? LAM 79 46(57.50) 33(42.50) ? ?
? LDT 33 21(64.71) 12(35.29) ? ?
? ADV 65 28(42.42) 37(57.58) ? ?
? ETV 114 77(67.54) 37(32.46) ? ?
? 联合用药 233 127(54.62) 106(45.38) ? ?
NAs相关耐药突变率[例(%)] 302 152(50.33) 150(49.67) χ2 = 0.001 0.981
不同NAs治疗耐药突变率[例(%)] ? ? ? χ2 = 7.383 0.117
? LAM 55 28(50.91) 27(49.09) ? ?
? LDT 24 16(66.67) 8(33.33) ? ?
? ADV 32 13(40.62) 19(59.38) ? ?
? ETV 43 28(65.12) 15(34.88) ? ?
? 联合用药 148 72(48.65) 76(51.35) ? ?
用药时间( ± s,月) 524 42.00 ± 31.05 41.00 ± 31.83 t = 0.207 0.835
年龄( ± s,岁) 524 36.94 ± 11.47 43.91 ± 13.10 t = 6.486 < 0.001
HBV DNA ( ± s,log10 IU/ml) 524 5.35 ± 1.49 5.39 ± 1.56 t = 0.293 0.770
ALT( ± s,U/L) 524 99.30 ± 255.48 163.13 ± 269.27 t = 0.346 0.730
AST( ± s,U/L) 524 128.40 ± 193.46 116.17 ± 271.46 t = 0.646 0.519
表3 524例HBV感染者中NAs相关耐药突变位点伴随M204突变情况[例(%)]
表4 HBV B型和C型感染者NAs相关耐药突变位点[例(%)]
图1 B型和C型感染者M204I或M204V伴随突变位点分析
[1]
Shi YH. Correlation between hepatitis B virus genotypes and clinical outcomes[J]. Jpn J Infect Dis,2012,65(6):476-482.
[2]
Li X, Liu Y, Xin S, et al. Comparison of detection rate and mutational pattern of drug-resistant mutations between a large cohort of genotype B and genotype C hepatitis B virus-infected patients in North China[J]. Microb Drug Resist,2017,23(4):516-522.
[3]
中华医学会肝病学分会, 中华医学会感染病分会. 慢性乙型肝炎防治指南(2010年版)[J]. 中国医学前沿杂志,2011,3(1):66-82.
[4]
中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肿瘤学杂志,2011,16(10):929-946.
[5]
Liu BM, Li T, Xu J, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients[J]. Antivir Res,2010,85(3):512-519.
[6]
Fung J, Seto WK, Lai CL, et al. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy[J]. J Hepatol,2011,54(2):195-200.
[7]
Yu H, Yuan Q, Ge SX, et al. Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype "I" [J]. PLoS One,2010,5(2):e9297.
[8]
Zeng G, Wang Z, Wen S, et al. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China[J]. J Viral Hepat,2005,12(6):609-617.
[9]
Fujie H, Moriya K, Shintani Y, et al. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan[J]. Gastroenterology, 2001,120(6):1564-1565.
[10]
Wang Z, Tanaka Y, Huang Y, et al. Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China[J]. J Clin Microbiol,2007,45(5):1491-1496.
[11]
Yuasa R, Takahashi K, Dien B, et al. Properties of hepatitis B virus genome recovered from Vietnamese patients with fulminant hepatitis in comparison with those of acute hepatitis[J]. J Med Virol,2000,61(1):23-28.
[12]
Yao GB, Zhu M, Cui ZY, et al. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China[J]. J Dig Dis,2009,10(2):131-137.
[13]
Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection[J]. J Hepatol,2010,52(6):791-799.
[14]
Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety[J]. Am J Gastroenterol,2011,106(7):1264-1271.
[15]
Yang H, Westland CE, Delaney WE, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks[J]. Hepatology,2002,36(2):464-473.
[16]
Zöllner B, Sterneck M, Wursthorn K, et al. Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy[J]. J Clin Microbiol,2005,43(5):2503-2505.
[17]
Mirandola S, Sebastiani G, Rossi C, et al. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy[J]. Antiviral Res,2012,96(3):422-429.
[18]
Ji D, Liu Y, Li L, et al. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation[J]. J Clin Virol,2012,54(1):66-72.
[19]
Kwon SY, Park YK, Ahn SH, et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients[J]. J Virol,2010,84(9):4494-4503.
[20]
He X, Wang F, Huang B, et al. Detection and analysis of resistance mutations of hepatitis B virus[J]. Int J Clin Exp Med,2015,8(6):9630-9639.
[21]
Zhang HY, Liu LG, Ye CY, et al. Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016)[J]. Virus Genes,2018,54(1):41-47.
[22]
Liu Y, Wang C, Zhong Y, et al. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection[J]. J Viral Hepat,2011,18(4): e29-e39.
[23]
Li XG, Liu BM, Xu J, et al. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China[J]. J Med Virol,2012,84(2):207-216.
[24]
孙秘书, 王贵强, 张伟. 拉米夫定经治慢性乙型肝炎患者治疗现状调查分析[J]. 中国预防医学杂志,2012,13(1):18-22.
[25]
Inoue J, Ueno Y, Wakui Y, et al. Four year study of lamivudine and adefovir combination therapy in lamivudine resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern[J]. J Viral Hepat,2011,18(3):206-215.
[26]
Qin B, Zhou Y, Zhou G, et al. Substitutions of rtL228 and/or L229 are involved in the regulation of replication and HBsAg secretion in hepatitis B virus, and do not affect susceptibility to nucleos(t)ide analogs[J]. Mol Med Rep,2017,16(6):9678-9684.
[27]
Lee HW, Chang HY, Yang SY, et al. Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy[J]. J Clin Virol,2014,60(3):313-316.
[1] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[2] 巨春蓉, 门同义, 薛武军. 实体器官移植后难治性/耐药性巨细胞病毒感染诊疗进展[J/OL]. 中华移植杂志(电子版), 2024, 18(02): 86-92.
[3] 邢嘉翌, 龚佳晟, 祝佳佳, 陆群. 肺癌化疗患者继发肺部感染的病原菌耐药性及炎症因子变化分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 714-718.
[4] 杨慧, 郭丽娟, 冯晓丹, 李静, 黄成谋, 蔡兴锐, 覃英娇, 王远礼. 非小细胞肺癌铂类药物耐药mi RNA表达特征及预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 719-724.
[5] 刘春军, 严方方, 王宝锋, 常婷婷, 郭红红, 李志强. 替加环素联合人免疫球蛋白治疗XDRAB致VAP 的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 797-800.
[6] 殷国青, 曾莉, 贺斌峰, 孙芬芬. Rab26负性调控Nrf2增强肺癌耐药细胞对奥希替尼的敏感性[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 349-355.
[7] 王蕊, 林先萍, 李盼盼. 铜绿假单胞菌感染肺炎菌血症危险因素及耐药性分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 478-480.
[8] 张剑, 卢从华, 李江华, 林采余, 吴迪, 王治国, 聂乃夫, 何勇, 李力. 根据转录组学分析奥希替尼获得性耐药机制的研究[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 195-200.
[9] 庞红燕, 宫艳格, 王瑶杰, 孙海鹏, 张连勇. TTF-1与非小细胞肺癌铂类药物化疗相关性分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 303-306.
[10] 王向前, 李清峰, 陈磊, 丘文丹, 姚志成, 李熠, 吴荣焕. 姜黄素抑制肝细胞癌索拉非尼耐药作用及其调控机制[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 729-735.
[11] 王涛, 刘静, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗生素耐药背景下中医药防治腹膜透析相关性腹膜炎研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 340-344.
[12] 徐靖亭, 孔璐. PARP抑制剂治疗卵巢癌的耐药机制及应对策略[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 584-588.
[13] 虞岱瑶, 冯文莉. 不同状态下SAP2和STP1在白念珠菌伊曲康唑耐药中的作用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 283-294.
[14] 陈怡丽, 刘平娟, 郭鹏豪, 邓间开, 彭雅琴, 伍众文, 刘敏, 陈培松, 廖康. 全国细菌耐药监测网实践培训基地教学质量评价体系的建立与实践[J/OL]. 中华临床实验室管理电子杂志, 2024, 12(03): 155-161.
[15] 李佳佳, 李凌华, 吕诗韵, 冯凯, 刘琳珊, 钟海丹, 颜婵, 刘聪. 广州市病毒学抑制失败HIV/AIDS患者的耐药特征及影响因素分析[J/OL]. 中华卫生应急电子杂志, 2024, 10(04): 207-212.
阅读次数
全文


摘要